<DOC>
	<DOCNO>NCT02956746</DOCNO>
	<brief_summary>This single site , randomize , blind comparison immunogenicity , Imovax ( RVi ) Rabavert ( RVa ) rabies vaccines subject administer rabies immune globulin ( RIG ) SYN023 . Subjects randomize one four dose group : RVi + SYN023 , RVi+RIG , RVa+SYN023 RVa+RIG . The initial dose RVi RVa co-administered either RIG SYN023 ) . Rabies virus neutralize activity ( RVNA ) blood level SYN023 measure remainder trial rest five RVi RVa dose give . The study last 112 day . SYN023 concentration anti-SYN023 antibody also measure .</brief_summary>
	<brief_title>A Comparison Safety , Pharmacokinetics Pharmacodynamics Single Dose SYN023 Administered With Licensed Rabies Vaccines</brief_title>
	<detailed_description>Administered immunoglobulin direct vaccine antigens potential inhibit immune response vaccine . Both vaccination immune globulin use together post exposure prophylaxis rabies virus infection . SYN023 ( mixture two monoclonal antibody CTB011 CTB012 ) may use instead human rabies immune globulin . Since risk antagonism vaccine induce immunity SYN023 , rabies immune globulin , necessary study possible interaction two agent might use concurrently . This single site , randomize , blind comparison immunogenicity , Imovax ( RVi ) Rabavert ( RVa ) rabies vaccine administer concurrently rabies immune globulin ( RIG ) SYN023 . Subjects randomize one four dose group : RVi + SYN023 , RVi + RIG , RVa+SYN023 RVa + RIG . The initial dose RVi RVa co-administered either RIG SYN023 ) . The remain 4 dos RVi RVa administer intramuscularly specify product labeling . Serum rabies virus neutralize activity ( RVNA ) serum concentration component SYN023 measure remainder trial rest five RVi RVa dose give . Adverse event collect duration trial . The study last 112 day . Anti-SYN023 antibody also measure .</detailed_description>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>1 . Male female subject 18 50 year age , inclusive 2 . Body mass index 18 30 kg/m² , inclusive 3 . Female subject physically capable pregnancy ( i.e. , sterilize still menstruate within 1 year last menses menopausal ) must : 1 . Agree avoid pregnancy 28 day prior Study Day 0 duration study . 2 . If sexual relationship man , use acceptable method avoid pregnancy period . Acceptable method avoid pregnancy include : use least two form contraception , include use partner barrier method ( e.g. , male condom intravaginal spermicide ) one form contraception . 4 . Women childbearing potential must negative serum pregnancy test within 24 hour precede receipt dose . 5 . Can understand sign inform consent document , communicate investigator provide update contact information need duration study , current plan move study area duration study , understand comply requirement protocol . 1 . Oral temperature ≥37.5°C screen 2 . Complete blood count ( CBC ) platelet count abnormal value ( &gt; 5 % upper limit normal [ ULN ] &gt; 5 % low limit normal [ LLN ] per local laboratory parameter ) screen exception absolute lymphocyte count . 3 . Abnormally elevated aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin , alkaline phosphatase ( ALP ) , creatinine ( Cr ) value screen ( however single test AST , ALT ALP may &gt; 10 % ULN per local laboratory parameter ) 4 . Abnormal PT ( INR ) PTT 5 . Abnormal screen urinalysis result , per investigator , clinically significant , screen urine dipstick result ≥2+ protein 6 . Positive screening urine test illicit drug ( opiate , cocaine , amphetamine methamphetamine , barbiturate , benzodiazepine , tetrahydrocannabinol , PCP , MDMA , methadone ) 7 . History evidence autoimmune disease 8 . History evidence past , present , future possible immunodeficiency state , include laboratory evidence human immunodeficiency virus ( HIV ) 1 2 infection 9 . History evidence chronic hepatitis 10 . History evidence rabies infection 11 . History evidence acute chronic disease , opinion investigator , may interfere evaluation safety immunogenicity drug compromise safety subject ; example clinically relevant history respiratory , thyroid , gastrointestinal , renal , hepatic , hematological , lymphatic , oncologic , cardiovascular , psychiatric , neurological , musculoskeletal , genitourinary , infective , inflammatory , immunological , dermatological connective tissue disease 12 . History evidence allergic disease reaction , include adverse response therapeutic monoclonal antibody , opinion investigator , may compromise safety subject 13 . History noncompliance , opinion investigator , make unlikely subject comply protocol 14 . Previous exposure rabies vaccine 15 . Receipt immunoglobulin blood product within 90 day prior Study Day 0 16 . Receipt immunosuppressive medication inhale topical immunosuppressant drug within 45 day prior Study Day 0 17 . Body weight great 90 kg . 18 . History evidence IgA deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>